Wysa will use the funding for expansion in the U.S, U.K., India and other global markets, to introduce multilingual services and to make the platform accessible from global-messaging service WhatsApp, it said in a company news release.
Wysa was designated an FDA breakthrough device, a specification given by the FDA to devices that effectively manage chronic conditions. Wysa was found to be more effective than standard orthopedic and counseling services at treating chronic pain and associated depression and anxiety.
“Wysa has … developed into a clinically validated, powerful tool to proactively manage mental health and well-being, Ramakant Vempati, the platform’s co-founder, said in the news release. “With this funding, we look forward to scaling up further and helping millions of more people.”
